The U.S. Food and Drug Administration has announced plans to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products for American consumers and patients.
This move builds upon the agency's Office of Inspection and Investigations Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies, FDA said in a press release.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com